Quantifying the Titer and Quality of Adenovirus Stocks
The broad application of recombinant adenoviruses to the development of vaccines and gene therapy vectors has encouraged the development of molecular assays for the facile quantitation of adenoviral particles and the assignment of their infectious potency. The Genome Quantitation Assay (GQA) and the QPCR-Based Potency Assay (QPA) developed for adenoviruses offer the attributes of precision, rapidity, and high throughput either performed manually or facilitated by simple automated liquid handling systems. These assay attributes allow for accelerated process development support and product characterization and release. The assays for adenovirus could offer the additional advantage in that their quantitation is based on viral replication independent of cytopathology permitting quantitation of serotypes that cause minimal cytopathic effect (CPE) in 293 cells and specificity that allows the components of multivalent vaccines to be discriminated and quantitated for release.
- Expressed Sequence Tags: Analysis and Annotation
- Generation of Yeast Artificial Chromosome Transgenic Mice by Intracytoplasmic Sperm Injection
- Melting Curve Assays for DNA Methylation Analysis
- Sustained Heterologous Transgene Expression in Mammalian and Avian Cell Lines
- Detection of Prokaryotic Cells with Fluorescence In Situ Hybridization
- Using the Quantitative Competitive RT-PCR Technique to Analyze Minute Amounts of Different mRNAs in Small Tissue Samples
- Pulsed-Field Gel Electrophoresis of Bacterial Chromosomes
- Cloning, Expression, and Functional Analysis of Genomic miRNA Using Retroviral System in Cancer Cells
- Isolation of Messenger RNA from Plant Tissues
- Cloning of ES Cells and Mice by Nuclear Transfer